Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Anixa redirects resources to therapeutics, vaccines in high-need patients » 17:02
07/02/20
07/02
17:02
07/02/20
17:02
ANIX

Anixa Biosciences

$3.16 /

+0.19 (+6.40%)

Anixa Biosciences…

Anixa Biosciences announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek liquid biopsy technology. Going forward, Anixa's operations will center entirely on the development and expansion of its therapeutics and vaccine portfolio, which includes a cancer immunotherapy program being developed in partnership with the Moffitt Cancer Center, that uses chimeric endocrine receptor T-cell technology, a novel type of CAR-T. Anixa is also developing a cancer vaccine technology addressing breast cancer with a specific focus on triple negative breast cancer, the most lethal form of the disease, in partnership with the Cleveland Clinic. Anixa will continue drug discovery and development of Covid-19 therapies, in partnership with OntoChem, GmbH. In addition, Anixa will continue to examine emerging therapeutic technologies for further development. "Due to the evolving dynamics of the diagnostics market during this pandemic and projected disruptions in this industry, we see greater opportunity to benefit patients and our shareholders as a therapeutics-directed company," said Amit Kumar, Ph.D., Chief Executive Officer of Anixa. "The pandemic and market forces have made it clear that we need to pivot. Our confidence in the Cchek(TM) technology remains undiminished, but we feel the prudent decision is to suspend work on diagnostics at this time."

ShowHide Related Items >><<
ANIX Anixa Biosciences
$3.16 /

+0.19 (+6.40%)

ANIX Anixa Biosciences
$3.16 /

+0.19 (+6.40%)

12/30/19 B. Riley FBR
Anixa Biosciences price target lowered to $8 from $11.25 at B. Riley FBR
Over a month ago
Hot Stocks
Anixa Biosciences, OntoChem synthesize four potential COVID-19 compounds » 08:37
06/01/20
06/01
08:37
06/01/20
08:37
ANIX

Anixa Biosciences

$2.29 /

-0.005 (-0.22%)

Anixa Biosciences…

Anixa Biosciences announced that the company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing. Anixa and OntoChem announced their partnership on April 20 and announced discovery of its first potential Covid-19 candidate two weeks later on May 4.

ShowHide Related Items >><<
ANIX Anixa Biosciences
$2.29 /

-0.005 (-0.22%)

ANIX Anixa Biosciences
$2.29 /

-0.005 (-0.22%)

12/30/19 B. Riley FBR
Anixa Biosciences price target lowered to $8 from $11.25 at B. Riley FBR
Hot Stocks
Anixa, OntoChem announce discovery of first COVID-19 therapeutic candidate » 06:48
05/04/20
05/04
06:48
05/04/20
06:48
ANIX

Anixa Biosciences

$1.84 /

-0.05 (-2.65%)

Anixa Biosciences…

Anixa Biosciences announced that it, with partner OntoChem GmbH, has identified its first therapeutic candidate against Covid-19, and has advanced the compound into biological testing. This is the first therapeutic candidate identified from the strategic partnership recently established by Anixa and OntoChem to evaluate over 1.2 billion molecules through an in silico study to identify potential therapies for patients infected by SARS-CoV-2, the virus that causes Covid-19. Anixa believes that drugs targeting the molecular biology of SARS-CoV-2 will produce more powerful medicines than the drugs currently being evaluated in trials, most of which were repurposed from other diseases. This first compound is expected to disrupt the interaction of the virus's endoribonuclease with a host human protein that is necessary for the virus to replicate upon infection. Disrupting this protein-protein interaction is expected to dramatically reduce or eliminate the virus's ability to cause disease. The biological testing will initially determine how well this compound binds to the endoribonuclease, and then how well this translates into reducing viral replication in human host cells.

ShowHide Related Items >><<
ANIX Anixa Biosciences
$1.84 /

-0.05 (-2.65%)

12/30/19 B. Riley FBR
Anixa Biosciences price target lowered to $8 from $11.25 at B. Riley FBR
Hot Stocks
Anixa Biosciences' Ccheck Liquid Biopsy featured in peer-reviewed article » 07:12
04/23/20
04/23
07:12
04/23/20
07:12
ANIX

Anixa Biosciences

$1.95 /

+0.02 (+1.04%)

Anixa Biosciences…

Anixa Biosciences announced the publication of a peer-reviewed journal article in Biomarker Insights. The article supports the use of Anixa's Cchek early cancer detection technology as a tool to improve prostate cancer detection and reduce unnecessary biopsies. Cchek is an artificial intelligence-driven platform developed as a blood test to detect solid tumors by screening for the body's immune response to the presence of a malignancy. The journal article, co-authored by Anixa with collaborators from the Wistar Institute, the MD Anderson Cancer Center at Cooper and the Cooper Medical School of Rowan University and New Jersey Urology, highlights study data demonstrating Cchek's ability to distinguish healthy men from high-risk prostate cancer patients with a sensitivity of 96.6% and a specificity of 87.5%. In addition, Cchek demonstrated an ability to distinguish, among men scheduled for biopsy, those with high-risk prostate cancer from those with benign conditions or low-grade cancer, for which surgery is not required and a biopsy is unnecessary.

ShowHide Related Items >><<
ANIX Anixa Biosciences
$1.95 /

+0.02 (+1.04%)

12/30/19 B. Riley FBR
Anixa Biosciences price target lowered to $8 from $11.25 at B. Riley FBR
Hot Stocks
Anixa , OntoChem announce collaboration to develop novel COVID-19 therapeutics » 06:41
04/20/20
04/20
06:41
04/20/20
06:41
ANIX

Anixa Biosciences

$1.94 /

+0.01 (+0.52%)

Anixa Biosciences…

Anixa Biosciences announced that it has entered into a strategic collaboration with OntoChem GmbH to discover and develop anti-viral drug candidates for COVID-19. While Anixa has primarily focused in oncology, its nimble and flexible capital efficient business model, enables it to effectively address new critical unmet needs such as this dynamic pandemic. Further, Dr. Kumar has previous experience working in the infectious disease area, including work done with the SARS-virus that emerged in 2003. In fact, Dr. Kumar and his company at that time, worked with a number of government agencies including the Department of Defense to develop technologies to detect and monitor deadly infectious diseases. In performing that work, Dr. Kumar made presentations to various members of the U.S. Senate and House regarding upcoming and emerging diseases. Considering the acute public health and economic problems caused by COVID-19, Anixa felt it was important to utilize its expertise and leverage its business model to address this pandemic. The Anixa-OntoChem COVID-19 program will focus on two specific proteins of the coronavirus. The first protein is the main protease, Mpro, which is an enzyme of the virus that severs a large poly-peptide into functional proteins that enable the virus to replicate in the human host. The program will attempt to identify molecules that inhibit the function of this enzyme, and potentially stop or slow down the virus' ability to replicate and cause disease. Since this protease does not have human analogs, potential inhibitors may not affect any human proteins and therefore toxic side effects may be minimized. Several crystal structures of this enzyme have been published, including a high resolution image published on March 20, 2020 (Science 2020, DOI 10.1126/science.abb3405), which induced Dr. Kumar's interest in targeting this protein. Using high performance computing and artificial intelligence, Anixa and OntoChem will identify molecules in the various libraries comprised of 1.2 billion compounds, which might inhibit this protein. One very attractive chemical library is a proprietary, multi-component reaction library created and owned by OntoChem utilizing its extensive database of chemical reactions. The second target is an endoribonuclease, which plays a role in breaking up the ribonucleic acid, or the genetic content, of the virus. Recent studies have demonstrated that the endoribonuclease of many viruses, including the SARS virus of 2003 and it is believed the SARS-CoV-2, binds to a human host protein. This protein-protein interaction appears to dramatically increase the infectivity of the virus. Because this interaction between a viral protein and a human protein appears to be common to many viruses, compounds that are able to effectively disrupt this interaction could function as broad spectrum anti-virals in addition to addressing COVID-19.

ShowHide Related Items >><<
ANIX Anixa Biosciences
$1.94 /

+0.01 (+0.52%)

12/30/19 B. Riley FBR
Anixa Biosciences price target lowered to $8 from $11.25 at B. Riley FBR
Over a quarter ago
Recommendations
Anixa Biosciences price target lowered to $8 from $11.25 at B. Riley FBR » 08:56
12/30/19
12/30
08:56
12/30/19
08:56
ANIX

Anixa Biosciences

$2.85 /

-0.09 (-3.06%)

B. Riley FBR analyst…

B. Riley FBR analyst Andrew D'Silva lowered his price target for Anixa Biosciences shares to $8.00 from $11.25 after several recent events that he views as "mixed," including the commercial launched of its Cchek confirmatory test for prostate cancer and the update that its CER-T cell candidate will need further genetic engineering that is extending the timeline for an IND to be filed. Getting a commercially ready offering into the market is a clear positive, but pushing back its IND filing for its CER-T candidate adds risks to the equation, said D'Silva, who maintains a Buy rating on Anixa shares.

Hot Stocks
Anixa Biosciences announces commercial launch of Cchek » 06:55
12/16/19
12/16
06:55
12/16/19
06:55
ANIX

Anixa Biosciences

$3.27 /

-0.55 (-14.40%)

Anixa Biosciences…

Anixa Biosciences announced the commercial launch of its Cchek Prostate Cancer Confirmation test, "the first test developed with the Cchek artificial intelligence driven, flow cytometry based, liquid biopsy technology platform." The Cchek PCC test will be offered as a CLIA validated test through Anixa's partner laboratory, ResearchDx. This test has been independently validated by ResearchDx and is designed to confirm the need for prostate biopsy, as a means to minimize unnecessary invasive procedures and reduce healthcare costs associated with traditional methods of prostate cancer diagnosis and the associated adverse events.

Hot Stocks
Fly Intel: Pre-market Movers » 09:01
12/13/19
12/13
09:01
12/13/19
09:01
SNAP

Snap

$14.45 /

+0.22 (+1.55%)

, SRPT

Sarepta

$100.39 /

-1.15 (-1.13%)

, ADBE

Adobe

$305.76 /

+2.01 (+0.66%)

, ORCL

Oracle

$56.47 /

+0.16 (+0.28%)

, XPER

Xperi

$19.91 /

+0.44 (+2.26%)

, EXEL

Exelixis

$17.68 /

+0.05 (+0.28%)

, AVGO

Broadcom

$327.39 /

+7.53 (+2.35%)

, ANIX

Anixa Biosciences

$3.82 /

-0.05 (-1.29%)

, PTEN

Patterson-UTI

$10.38 /

+0.29 (+2.87%)

, AQST

Aquestive Therapeutics

$6.73 /

-0.97 (-12.60%)

UP AFTER EARNINGS: Adobe…

UP AFTER EARNINGS: Adobe (ADBE), up 2%. ALSO HIGHER: Snap (SNAP), up 2% after JMP Securities analyst Ronald Josey upgraded the stock to Outperform from Market Perform with a $20 price target. The analyst is "incrementally confident" in Snap's ability to grow its user base, increase engagement, and improve overall monetization as the service attracts more advertisers and share of advertising budgets... Xperi (XPER), up 2% after raising Q4 and FY19 billings outlook... Exelixis (EXEL), up 4% after Genentech announced the Phase III IMspire150 study met its primary endpoint of progression-free survival. In late 2006, Exelixis entered into a worldwide collaboration agreement with Genentech, under which Exelixis received initial upfront and milestone payments for signing the agreement and submitting the IND... Sarepta (SRPT), up 32% after announcing that the FDA has approved VYONDYS 53, an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy in patients with a confirmed mutation amenable to exon 53 skipping. DOWN AFTER EARNINGS: Oracle (ORCL), down 2%... Broadcom (AVGO), down 1%. ALSO LOWER: Patterson-UTI (PTEN), down 2% after JPMorgan analyst Sean Meakim downgraded shares to Underweight from Neutral with a price target of $6, down from $7... Anixa Biosciences (ANIX), down 2% after announcing optimization work for its CAR-T therapy may take an additional year, resulting in the filing of the IND in late 2020, with clinical trials to commence in 2021... Aquestive Therapeutics (AQST), down 18% after its 7M share secondary priced at $5.00 per share.

ShowHide Related Items >><<
SNAP Snap
$14.45 /

+0.22 (+1.55%)

12/13/19 JMP Securities
Snap upgraded to Outperform from Market Perform at JMP Securities
11/25/19 Loop Capital
Snap upgraded to Buy from Hold at Loop Capital
11/25/19 Loop Capital
Snap upgraded to Buy from Hold at Loop Capital
10/23/19
Fly Intel: Top five analyst upgrades
SRPT Sarepta
$100.39 /

-1.15 (-1.13%)

12/13/19 H.C. Wainwright
Sarepta price target raised to $260 from $160 at H.C. Wainwright
12/13/19 Janney Montgomery Scott
Sarepta price target raised to $175 from $160 at Janney Montgomery Scott
12/13/19 Cantor Fitzgerald
Sarepta should rally 20%-30% on golodirsen approval, says Cantor Fitzgerald
12/13/19 RBC Capital
Sarepta price target raised to $215 from $200 at RBC Capital
ADBE Adobe
$305.76 /

+2.01 (+0.66%)

12/13/19 Jefferies
Adobe price target raised to $370 from $350 at Jefferies
12/13/19 Credit Suisse
Adobe price target raised to $350 from $325 at Credit Suisse
12/13/19 Stifel
Adobe price target raised to $350 from $325 at Stifel
12/13/19 Barclays
Adobe price target raised to $350 from $330 at Barclays
ORCL Oracle
$56.47 /

+0.16 (+0.28%)

12/13/19 Raymond James
Oracle price target lowered to $57 from $61 at Raymond James
12/13/19 Barclays
Oracle shares to come under near-term pressure, says Barclays
12/13/19 Wedbush
Oracle price target raised to $56 from $55 at Wedbush
11/13/19 Piper Sandler
Oracle assumed with a Neutral at Piper Jaffray
XPER Xperi
$19.91 /

+0.44 (+2.26%)

07/02/19 B. Riley FBR
Xperi selloff since Q1 results brings positive setup, says B. Riley FBR
02/21/19 Craig-Hallum
Xperi price target raised to $32 from $28 at Craig-Hallum
EXEL Exelixis
$17.68 /

+0.05 (+0.28%)

11/13/19 BofA
Exelixis initiated with a Buy at BofA/Merrill
10/31/19 Piper Sandler
Exelixis price target lowered to $35 from $45 at Piper Jaffray
10/15/19 Guggenheim
Exelixis price target lowered to $25 from $33 at Guggenheim
10/08/19 BMO Capital
Exelixis price target lowered to $19 from $23 at BMO Capital
AVGO Broadcom
$327.39 /

+7.53 (+2.35%)

12/13/19 JPMorgan
Broadcom price target raised to $380 from $350 at JPMorgan
12/13/19 Wells Fargo
Broadcom price target raised to $330 from $300 at Wells Fargo
12/13/19 Mizuho
Broadcom price target raised to $365 from $340 at Mizuho
12/11/19 Oppenheimer
Broadcom price target raised to $350 from $315 at Oppenheimer
ANIX Anixa Biosciences
$3.82 /

-0.05 (-1.29%)

PTEN Patterson-UTI
$10.38 /

+0.29 (+2.87%)

12/13/19 JPMorgan
Patterson-UTI downgraded to Underweight from Neutral at JPMorgan
12/12/19 Deutsche Bank
Deutsche Bank initiates 'Catalyst Call Buy' on Halliburton
12/03/19 Credit Suisse
Patterson-UTI downgraded to Underperform from Neutral at Credit Suisse
11/19/19 Deutsche Bank
Patterson-UTI initiated with a Sell at Deutsche Bank
AQST Aquestive Therapeutics
$6.73 /

-0.97 (-12.60%)

12/02/19 JMP Securities
Aquestive Therapeutics NDA filing a positive sign, says JMP Securities
12/02/19 H.C. Wainwright
Aquestive Therapeutics price target raised to $14 from $12 at H.C. Wainwright
07/16/19 H.C. Wainwright
Aquestive Therapeutics price target raised to $12 from $10 at H.C. Wainwright
06/10/19 H.C. Wainwright
Aquestive Therapeutics recent selloff unwarranted, says H.C. Wainwright
  • 13
    Dec
Hot Stocks
Anixa Biosciences provides update on CAR-T program » 07:00
12/13/19
12/13
07:00
12/13/19
07:00
ANIX

Anixa Biosciences

$3.82 /

-0.05 (-1.29%)

Anixa Biosciences…

Anixa Biosciences announced an update regarding the chimeric antigen receptor T-cell, or CAR-T, technology it is developing with its partner, Moffitt Cancer Center. Experimental results reported indicate that the potential efficacy of this technology as a treatment for ovarian cancer could be improved through additional genetic engineering. CAR-T therapy begins with the extraction and isolation of T-cells from individual cancer patients. A viral vector is then used to transform these T-cells to produce on their surface a molecule that enables the cell, once re-infused into the patient, to find cancer cells and kill them. With Anixa's CAR-T therapy, the T-cells are transformed to express on their surface, the follicle stimulating hormone, or FSH, which targets cells that are expressing follicle stimulating hormone receptor, or FSHR. Recent experimental results indicate that with additional engineering, the transformed cells produced by the viral vector currently being used could express much higher levels of FSH, enabling a more potent cancer killer. In order to increase the potency of the transformed T-cells, researchers at Moffitt will create an improved viral vector and verify experimentally that it will result in a more powerful cancer therapy. As a result, the decision has been made to optimize the therapy and file an investigational new drug, or IND, application with the FDA in the future. This optimization work may take an additional year, resulting in the filing of the IND in late 2020, with clinical trials to commence in 2021.

Hot Stocks
Anixa Biosciences announces Cchek study collaboration with UCA » 07:13
11/22/19
11/22
07:13
11/22/19
07:13
ANIX

Anixa Biosciences

$3.50 /

-0.11 (-3.05%)

Anixa Biosciences…

Anixa Biosciences announced a collaboration with Urology Centers of Alabama, or UCA, in the Cchek early prostate cancer detection study. UCA will provide patient samples in Anixa's ongoing study, including support of clinical validation of Anixa's Cchek Prostate Cancer Confirmation test. UCA is one of several sites across the U.S. participating in this study.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.